Deutsche Bank
ACAD icon

Deutsche Bank’s Acadia Pharmaceuticals ACAD Stock Holding History

Deutsche Bank’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-200
Closed -$7K – 5119
2015
Q4 		$7K Buy
+200
New +$7.05K ﹤0.01% 4995

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Deutsche Bank's ACAD Position: Q2 2026 in Review

Deutsche Bank reduced its Acadia Pharmaceuticals (ACAD) stake by 69% in Q2 2026, selling an estimated $12.8M and leaving 257,759 shares worth $6.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1236.

Deutsche Bank first reported a position in ACAD in Q2 2013 and has held it in 53 quarters since. The position peaked at $56M in Q4 2020. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Deutsche Bank held 257,759 shares of Acadia Pharmaceuticals worth $6.52M as of Q2 2026.
  • Deutsche Bank sold 582,655 Acadia Pharmaceuticals shares in Q2 2026, an estimated $12.8M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1236 holding.
  • Deutsche Bank first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Deutsche Bank's Acadia Pharmaceuticals position peaked at $56M in Q4 2020.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.